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Abstract
Background: The androgen receptor splice variant-7 (AR-V7) has been implicated in the
development of castration-resistant prostate cancer (CRPC) and resistance to abirater-
one and enzalutamide.
Objective: To develop a validated assay for detection of AR-V7 protein in tumour tissue
and determine its expression and clinical signiﬁcance as patients progress from hor-
mone-sensitive prostate cancer (HSPC) to CRPC.
Design, setting, and participants: Following monoclonal antibody generation and vali-
dation, we retrospectively identiﬁed patients who had HSPC and CRPC tissue available
for AR-V7 immunohistochemical (IHC) analysis.
Outcome measurements and statistical analysis: Nuclear AR-V7 expression was deter-
mined using IHC H score (HS) data. The change in nuclear AR-V7 expression from HSPC
to CRPC and the association between nuclear AR-V7 expression and overall survival (OS)
was determined.
Results and limitations: Nuclear AR-V7 expression was signiﬁcantly lower in HSPC
(median HS 50, interquartile range [IQR] 17.5–90) compared to CRPC (HS 135, IQR 80–
157.5; p < 0.0001), and in biopsy tissue taken before (HS 80, IQR 30–136.3) compared to
after (HS 140, IQR 105–167.5; p = 0.007) abiraterone or enzalutamide treatment. Lower
nuclear AR-V7 expression at CRPC biopsy was associated with longer OS (hazard ratio
1.012, 95% conﬁdence interval 1.004–1.020; p = 0.003). While this monoclonal antibody
primarily binds to AR-V7 in PC biopsy tissue, it may also bind to other proteins.
Conclusions: We provide the ﬁrst evidence that nuclear AR-V7 expression increases
with emerging CRPC and is prognostic for OS, unlike antibody staining for the AR N-
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agents targeting AR splice variants are needed to test this hypothesis and further improve
patient outcome from CRPC.
Patient summary: In this study we found that levels of the protein AR-V7 were higher in
patients with advanced prostate cancer. A higher level of AR-V7 identiﬁes a group of
patients who respond less well to certain prostate cancer treatments and live for a shorter
period of time.
# 2016 European Association of Urology. Published by Elsevier B.V. This is an open access
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Patients with advanced prostate cancer initially respond to
androgen deprivation therapy (ADT), but inevitably relapse
with fatal castration-resistant prostate cancer (CRPC); there
is increasing evidence of ongoing androgen receptor (AR)
signalling with rising prostate specific antigen (PSA),
increased steroidogenesis, and occasionally activating point
mutations within the AR ligand-binding domain [1–5]. This
led to the development of abiraterone acetate (AA) and
enzalutamide (EZ), which effectively target AR signalling in
CRPC and improve patient outcome [6–9]. However, resis-
tance to both agents is common and may be due in part to
constitutively active AR splice variants (AR-Vs), of which AR
variant-7 (AR-V7) is the most well studied. Consistent with
this, a recent study demonstrated limited responses to AA
and EZ in patients with detectable levels of AR-V7 RNA in
circulating tumour cells [3].
AR-V7 is truncated after canonical AR exon 3, with
inclusion of a cryptic exon 3b (CE3b) derived from an intron
in the expressed protein [10]. AR-V7 expression is
associated with a rearranged AR gene and can also be
produced by aberrant pre-mRNA splicing due to androgen
deprivation induced by castration, AA, EZ, or ARN-509
[4,11,12]. The ability of the intrinsically disordered AR N-
terminus to continue AR signalling in the absence of ligand
binding has been proven by deletion constructs [13]. Cas-
tration-resistant cell lines including 22Rv1 and the EZ-
resistant LNCaP95 harbour AR-Vs. Specific inhibition of AR-
V7 with siRNA to CE3b inhibits tumour growth [1,12,14].
Treatment with AA or EZ results in increased expression of
AR-Vs, with AR-V7 being the most highly expressed
[10,15,16]. Cell constructs in which AR-V7 is expressed are
resistant to drugs targeting the AR ligand-binding domain
[14]. AR-V7 expression may have utility as a predictive
biomarker and is an important therapeutic target.
Originally, studies indicated that AR-V7 heterodimerises
with full-length AR (AR-FL) [14,17]. This suggested that AR-
FL blockage would inhibit AR-V7 activity. However, AR-V7
also homodimerises to itself and heterodimerises with
other AR-Vs, binding to androgen response elements to
generate a signal independent of AR-FL [18,19]. Analysis of
this potentially key resistance mechanism in clinical
samples has been challenging because of low levels of
AR-V7 mRNA and the lack of a reproducible tumour tissue
assay. We established a validated assay and show for the
first time in matched tumour samples from the same
patients how AR-V7 expression changes from hormone-
sensitive prostate cancer (HSPC) to CRPC, and evaluate its
clinical significance. The data we report here are importantin the interpretation of an ongoing randomised trial using
this antibody to detect AR-V7 in circulating tumour cells as
a putative predictive biomarker in patients whose cancer
has progressed on EZ or AA (NCT02485691).
2. Materials and methods
2.1. Antibody generation and characterisation
2.1.1. Antibody generation
Several polyclonal antibodies were generated in four rabbits immunised
with a synthetic AR-V7 peptide containing the 16 amino acids of CE3b
(aa 630–645). Sera collected from immunised rabbits were puriﬁed and
screened by immunoprecipitation and western blotting of AR-V7–
transfected M12 cells. The polyclonal antibody H6253 was selected
because it demonstrated reactivity with a single band consistent with
AR-V7. A hybridoma was generated by fusing splenocytes with the
fusion partner cell line 240E-W2. The rabbit monoclonal antibody EP343
was selected from the ﬁnal hybridoma cell line and was further
characterised.
2.1.2. Cell lines
LNCaP95 cells were provided by Drs. Alan K Meeker and Jun Luo (Johns
Hopkins University, Baltimore, MD, USA) and cultured in RPMI
1640 medium supplemented with 10% charcoal-stripped foetal bovine
serum (FBS; Invitrogen, Carlsbad, CA, USA). M12 cells were provided by
Dr. Joy Ware (Virginia Commonwealth University, Richmond, VA, USA)
and cultured in RPMI 1640 supplemented with 5% FBS [20]. DU145,
22Rv1s, and PC3 cells were obtained fromATCC (Manassas, VA, USA) and
grown in their recommended culture medium containing 10% FBS at
37 8C in 5% CO2. LuCap xenografts were provided by Drs. Eva Corey and
Colm Morrisey (University of Washington, Seattle, WA, USA). M12 cells
expressing cumate-inducible 3FLAG-wtAR, 3FLAG-ARv567es, and
3FLAG-AR-V7 lentivirus were prepared using the SparQcumate switch
lentivector system (Systems Biosciences, Palo Alto, CA, USA). pCDH-EF1-
CymR-T2A-Puro vectors were packaged into lentiviral particles using
pPACK packaging systems (System Biosciences). To prepare stable cell
lines, M12 cells were infected with 1107 virus particles per 1  106
cells and then selected with 1 mg/ml puromycin (Invitrogen) for 10 d.
Stably transduced M12 lines were maintained in RPMI 1640 supple-
mented with 5% FBS, 0.01 mM dexamethasone (Sigma Aldrich, St. Louis,
MO, USA), 10 ng/ml epidermal growth factor (Invitrogen), 10 ml/l
insulin-transferrin-selenium (Cellgro, Tewksbury, MA, USA), 100 IU/ml
penicillin, and 100 mg/ml streptomycin at 37 8C with 5% CO2.
2.1.3. siRNA and quantitative RT-PCR
siRNA studies were performed with cells reaching 70% conﬂuence.
Cells were transfected with 50 nM siRNA (Supplementary Table 1) for
48 h using Lipofectamine RNA iMax (Life Technologies, Carlsbad, CA,
USA). Quantitative RT-PCR was performed on RNA isolated using Trizol
reagent according to the manufacturer’s instructions (Invitrogen). cDNA
was reverse-transcribed from total RNA (1 mg) using an iScript cDNA
synthesis kit (Bio-Rad, Hercules, CA, USA). Real-time PCR was performed
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time PCR system (Applied Biosystems, Foster City, CA, USA) according
to the manufacturer’s instructions. The probes used are listed in
Supplementary Table 2.
2.1.4. Western blotting and co-immunoprecipitation
Western blotting was performed on whole cell extracts prepared in lysis
buffer (50 mMHEPES, 150 mMNaCl, 1.5 mMEGTA, 1% TritonX-100)with
a complete protease inhibitor cocktail (Roche, Basel, Switzerland). Tissue
extract (from200-mmbiopsies embedded in optimal cutting temperature
compound) were prepared in lysis buffer and then sonicated (two rounds
of 10 s at 10W). The extracted protein concentration was determined
by bicinchoninic acid assay (Thermo Scientiﬁc, Waltham, MA, USA).
Protein extracts (20 mg) were separated on 4–12% NuPAGE Bis-Tris gel
(Invitrogen) by electrophoresis and subsequently electrotransferred onto
Immobilon-P membranes (Millipore, Billerica, MA, USA). Membranes
were blocked and antibodieswere diluted in 5%milk. The antibody for the
AR N-terminal domain (AR-NTD) was used at 1:5000 dilution (Dako,
Glostrup, Denmark) and AR-V7 at 1:1000. Immunodetection was
performed according to the manufacturer’s protocol using enhanced
chemiluminescence reagent (GE Health Care, Little Chalfont, UK). In
co-immunoprecipitation experiments, cells were lysed in cold Pierce IP
Lysis buffer (Thermo Scientiﬁc). Precleared cell lysate was incubated with
anti-FLAG M2 (Sigma Aldrich), anti-AR-V7, or anti-AR-NTD (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) antibodies overnight. Immune
complexes were collected using protein A/G Plus agarose beads and
analysed by immunoblotting as previously described [21].
2.2. Patient cohort and tissue analysis
2.2.1. Patients and tissue samples
Patients were identiﬁed from a population of men with metastatic CRPC
treated at the Royal Marsden NHS Foundation Trust. Patients with a
diagnosis of prostate adenocarcinoma with sufﬁcient formalin-ﬁxed,
parafﬁn-embedded (FFPE) matched archival and CRPC tissue for AR-V7
immunohistochemistry (IHC) were selected. One patient who had
received a drug targeting the AR N-terminus (EZN-4176) and two
patients with histology consistent with neuroendocrine differentiation
were excluded [22]. Archival tissue was obtained from prostate needle
biopsy, transurethral resection of the prostate (TURP), or prostatectomy
procedures. CRPC tissue was obtained from metastases within bone,
lymph node, soft tissue, or visceral organs. All tissue blocks were freshly
sectioned and only considered for IHC analyses if adequate material was
present (50 tumour cells; reviewed by D.N.R.). All patients had given
written informed consent and were enrolled in institutional protocols
approved by the Royal Marsden NHS Foundation Trust Hospital (London,
UK) ethics review committee (reference no. 04/Q0801/60). A total of
37 patients with CRPC had archival (diagnostic) and CRPC tissue
sufﬁcient for testing; four patients had archival tissue from CRPC TURP
samples and therefore 33 patients had matched HSPC and CRPC tissue
samples. Of the 37 patients who had CRPC biopsies, 35 had treatment
with AA or EZ and 12 had their CRPC biopsy performed before AA
treatment and had fully evaluable PSA response data. Demographic and
clinical data for each patient were retrospectively collected from the
hospital electronic patient record system.
2.2.2. Tissue analysis
IHC was performed using the rabbit AR-V7 monoclonal antibody clone
EP343 (Epitomics). Antigen retrieval was achieved by microwaving
slides in citrate buffer (pH 6.0) for 18 min at 800 W. Endogenous
peroxidase was blocked using 3% H2O2 solution. Blockingwas performed
using the protein block solution from a Novolink polymer detection
system (Leica, Wetzlar, Germany). EP343 was diluted 1:200 and tissue
was incubated for 1 h. The reaction was visualised using the Novolinkpolymer andDAB chromogen. Caseswere scored by a pathologist (D.N.R)
blinded to clinical data using the modiﬁed H score (HS) method, a semi-
quantitative assessment of staining intensity that reﬂects antigen
concentration [23]. HS was determined according to the formula: [(% of
weak staining)1]+ [(%ofmoderate staining)2]+ [(%of strong staining)
 3], yielding a range from 0 to 300 [23]. We used a mouse monoclonal
antibody clone (AR441, Dako) to test AR-NTD expression at 1:5000
dilution. Antigen retrieval was performed using pH8.1 Tris/EDTA solution
heated in a water bath. Cell pellets from 22RV1 and LNCaP95 cells were
used as positive controls for AR-V7 IHC and cell pellets from DU145 and
PC3 cells were selected as negative controls. For AR-NTD IHC, positive
controls included cell pellets from 22RV1 and LNCAP cells and benign
prostate tissue, and negative controls included cell pellets from DU145
and PC3 cells.
RNA in situ hybridisation was performed on freshly cut 4-mm
sections derived from FFPE blocks using an RNAscope 2.5 platform
(Advanced Cell Diagnostics [ACD], Hayward, CA, USA). Three ACD target
probes were used: AR probe, AR-V7, and PPIB (cyclophilin B) as a positive
control. For all probes, xenograft sections were subjected to mild
pretreatment conditions, while the standard pretreatment protocol was
used for patient sections. The slides were processed for standard signal
ampliﬁcation steps according to the manufacturer’s instructions.
2.2.3. Statistical analysis
HS data are reported as median values with interquartile range (IQR).
Wilcoxon signed-rank and Mann-Whitney tests were used to compare
differences in expression levels. Time to CRPC was deﬁned as the time
from diagnosis to biochemical and/or radiological progression on
luteinising hormone-releasing hormone (LHRH) agonist alone or with
anti-androgen if started before/or with LHRH agonist with castrate
serum level of testosterone. Median time to CRPC was estimated using
the Kaplan-Meier method; Cox regression modelling was used to
determine association with HS. Overall survival (OS) wasmeasured from
the date of CRPC biopsy to the date of last contact (1 patient on regular
follow up; censored at last contact) or date of death from any cause
(36 patients). The Kaplan-Meier product-limit method was used to
estimate median OS for patients grouped by tertiles (to ensure
approximately 10 events per group) for nuclear AR-V7 expression,
nuclear AR-NTD expression, and the nuclear AR-V7/AR-NTD expression
ratio. The association between protein expression and OS was
determined using univariate Cox regression models; linear trend tests
were evaluated by determining orthogonal polynomials. The association
between the magnitude of PSA decline at 12 wk and nuclear AR-V7
expression was evaluated using univariate linear regression models.
Biochemical response to AA was deﬁned as 50% decline in PSA from
baseline at 12 wk. Statistical analyses were performed using Prism v.6
(GraphPad, La Jolla, CA, USA) and SPSS v.21 (IBM, Armonk, NY, USA).
3. Results
3.1. Antibody production and specificity
Apolyclonal antibody (H6253) to CE3b of AR-V7was initially
developed. Antibody specificity was determined by immu-
noprecipitation and western blotting of AR-V7–transfected
M12 cell lysate (Supplementary Fig. 1A,B). Following
confirmation, fusions were performed and a rabbit mono-
clonal antibody that detected AR-V7, but not AR-FL or AR-
V567es, was generated (EP343; Fig. 1A,B). Next, endogenous
expression of AR-V7 in prostate cancer cell lines was
examined (Fig. 1C). Of note, nonspecific bandswere observed
for all cell lines. RT-PCRof PC3mRNA showed that noAR-V7–
specific RNAwas present (Supplementary Fig. 1C). To further
[(Fig._1)TD$FIG]
Fig. 1 – EP343 identifies the AR-V7 splice variant. Immunoprecipitation (IP) of M12 cells stably transfected with PCDNA3 plasmid expressing 3TFLAG-
tagged cDNAs encoding either AR-FL, ARv567es, or AR-V7. Following IP of cell lysates with a FLAG antibody, blots were probed for (A) AR-NTD or (B)
AR-V7 to determine the specificity of the EP343 antibody. (C) Immunoblot staining of various prostate cancer cell lines, both positive and negative for
AR-V7 and AR-FL, shows AR-V7 staining (top arrow) along with a number of nonspecific bands and AR-FL (bottom arrow). (D) LNCaP95s were
transfected with siRNAs targeting either cryptic exon 3B (si V7), exon 7 (si ex7), exon 1 (si ex1), scrambled SiRNA (si SCR), or an input control. Note
that siRNAs directed at components of AR-V7 (si V7 and si ex 1) reduced EP343 staining, but siRNA directed at exon 7 had no effect. (E) IHC on 22Rv1
(positive for AR-NTD and AR-V7), DU145 (negative for AR-NTD and AR-V7) and PC3s which are negative for AR-NTD and should be negative for AR-V7
but have obvious EP343 staining. Both PC3 and 22Rv1 were transfected with AR-V7 (cryptic exon 3B) siRNA and then pelleted for EP343 IHC staining.
The targeted siRNA reduced AR-V7 in 22Rv1 IHC but not in PC3.
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and AR-V7 was carried out. As expected, VCAP and 22Rv1
were positive for AR and AR-V7RNA,while PC3was negative
for both (Supplementary Fig. 2). To further demonstrate the
ability of the antibody to detect AR-V7, LNCaP95 cells were
transfected with siRNAs to ARexon1, ARexon7, AR-V7 CE3b,
or siRNA scrambled. Suppression of AR-V7 protein was
observed with siRNAs to exon 1 and CE3b, but not the
scrambled siRNA or exon 7, an exon absent from AR-V7
(Fig. 1D). Overall, these data indicate that the antibody binds
to AR-V7 but may bind to other proteins.
3.2. IHC
The AR-V7 antibody was next optimised for IHC. 22Rv1 was
positive for AR-V7 (HS 150) while DU145 showed no
reactivity (HS 0; Fig. 1E). To confirm that this was AR-V7,22Rv1 was treated with CE3b siRNA and a decrease in
staining was observed (HS 70; Fig. 1E). However, PC3 was
negative for AR-NTD but showed AR-V7 positivity that was
not decreased by CE3b siRNA (Fig. 1E). These data are
consistent with the western blot finding that this antibody
can react with nonspecific protein targets as well as AR-V7.
We next tested LuCaP xenografts for AR-V7 and AR-NTD
expression. In neuroendocrine lines, very low or undetect-
able levels of AR-FL and AR-V7 were observed (Supplemen-
tary Fig. 3C). By contrast, xenografts with detectable AR-V7
mRNA yielded positive IHC results (Supplementary Fig.
3A,B), further confirming that EP343 detects AR-V7 in tissue
by IHC analysis. Similar results were acquired by both
laboratories (LNCaP95, 22Rv1, PC3, and DU145 cell pellets),
demonstrating assay reproducibility.
In CRPC liver metastases, AR-V7 nuclear positivity was
observed in bile ducts that were AR-NTD negative
[(Fig._2)TD$FIG]
Fig. 2 – AR-V7 and AR-NTD protein and mRNA in prostate cancer cell lines and patient samples. (A) Protein and mRNA expression results for cell lines
and patient castration resistant prostate cancer (CRPC) biopsy lysates. Patient protein samples show that EP343 binds to AR-V7 and some nonspecific
band/s. Densitometry and qPCR results are normalised against 22Rv1 results. (B) AR-V7 and AR-NTD staining of patient hormone-sensitive prostate
cancer (HSPC) and CRPC tissues, highlighting increases in both AR-V7 and AR-NTD.
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observed for colorectal cancer and basal cells of benign
respiratory epithelium (Supplementary Figs. 4C and 5A).
Critically, no AR-V7 RNA was observed by RNA in situ
hybridisation (Supplementary Figs. 4B,D and 5B). These
data indicate that the antibody may also detect a non-CE3b
target. Critically, to ensure that the antibody was detecting
AR-V7 in our patient cohort, we carried out protein and RNA
isolation followed by western blotting and qPCR analysis on
fresh tissue from a selection of CRPC patients. Expression of
AR-V7 at the correct size was the major protein detected in
western blots (Fig. 2A).
3.3. Nuclear AR-V7 and AR-NTD expression increases as
prostate cancer becomes castration resistant, and increases further
with AA and/or EZ resistance
Matched HSPC and CRPC tissue was available from
33 patients to evaluate nuclear expression of AR-V7 and
AR-NTD (matched cohort; Supplementary Table 3). To
determine changes in nuclear AR-V7 and AR-NTD expres-
sion during progression from HSPC to CRPC, HS data
for expression were calculated from IHC (Fig. 2B). NuclearAR-V7 expression levels increased significantly (p < 0.0001)
as patients progressed from HSPC (median HS 50, IQR 17.5–
90) to CRPC (HS 135, IQR 80–157.5; Fig. 3A). Although
nuclear AR-V7 increased in 26 (79%) patients, seven (21%)
patients had tumourswith higher nuclear AR-V7 expression
in HSPC (HS 90, IQR 50–115) compared to CRPC (HS 40, IQR
30–100). Similar to AR-V7, median nuclear AR-NTD
expression in patients with HSPC (HS 80, IQR 60–110)
significantly increased (p < 0.0001) as tumours progressed
to CRPC (HS 180, IQR 95–215; Fig. 3B).
To determine the effect of AA or EZ treatment on
nuclear AR-V7 and AR-NTD expression, patients with
CRPC biopsies (n = 35; 31 patients from the matched
cohort and 4 patients with CRPC biopsies only) who
received treatment with AA or EZ were divided into two
groups: patients who had biopsies before AA or EZ
treatment (n = 14) and patients who had biopsies after
AA or EZ treatment (n = 21). These were compared to the
HSPC biopsies (33 patients from matched cohort). The
median time of CRPC biopsy was 3.9 mo (IQR 0–7.7)
before AA or EZ and 9.6 mo (IQR 6–23.6) after AA or EZ
treatment. Mean nuclear AR-V7 expression increased
from HSPC biopsies (HS 50, IQR 17.5–90) to a higher level
[(Fig._3)TD$FIG]
Fig. 3 – Nuclear AR-V7 and AR-NTD expression increases from hormone-sensitive prostate cancer (HSPC) to castration-resistant prostate cancer (CRPC).
(A) Nuclear AR-V7 immunohistochemical H score (HS) for matched HSPC and CRPC patient samples. Patients with decreased (grey line) and increased
(black line) nuclear AR-V7 expression are shown, with p values for a Wilcoxon matched-pairs signed-rank test. (B) Nuclear AR-NTD HS for matched
HSPC and CRPC patient samples. Patients with decreased (grey line) and increased (black line) nuclear AR-NTD expression are shown, with p values for
a Wilcoxon matched-pairs signed-rank test. (C) Nuclear AR-V7 HS for HSPC biopsies (orange circles), CRPC biopsies before abiraterone acetate (AA) and
enzalutamide (EZ) treatment (black squares), and CRPC biopsies after AA or EZ (grey triangles). Black crosshairs denote the median HS with
interquartile range, and p values are for Mann-Whitney tests. (D) Nuclear AR-NTD HS for HSPC biopsies (orange circles), CRPC biopsies before AA or EZ
(black squares), and CRPC biopsies after AA or EZ (grey triangles). Black crosshairs denote the median HS with interquartile range, and p values are for
Mann-Whitney tests.
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IQR 30–136.3) to the highest level after AA or EZ treatment
(HS 140, IQR 105–167.5; Fig. 3C). The increase in nuclear
AR-V7 expression between HSPC and after AA or EZ
treatment was highly significant (p < 0.0001), as was the
increase in nuclear AR-V7 between pre and post AA or EZ
(p = 0.007) treatment biopsies. However, the difference in
nuclear AR-V7 expression between HSPC and biopsies
before AA or EZ treatment was not significant (p = 0.139;
Fig. 3C). Median nuclear AR-NTD expression increased
from HSPC biopsies (HS 80, IQR 60–110) to CRPC biopsies
before AA or EZ treatment (HS 210, IQR 165–250; Fig. 3D).
However, median nuclear AR-NTD expression decreased
in CRPC biopsies after (HS 130, IQR 87.5–215) compared to
before AA or EZ treatment (Fig. 3D). Differences in AR-NTD
expression levels among all the groups were statistically
significant.3.4. Nuclear AR-V7 expression in HSPC is correlated with time
to castration resistance
Thirty-three patients had HSPC biopsies and all patients
developed CRPC whether treated with systemic therapy or
radical treatment (prostatectomy and/or radiotherapy). The
median time to development of CRPCwas 22.3months (95%
confidence interval [CI] 14.3–30.3). Fifteen (45.5%) patients
were treated with LHRH agonist with or without anti-
androgen therapy, and eighteen (54.5%) patients received
radical (radiotherapy or surgery) treatment. The median
time to CRPC was longer in patients that received radical
therapy than among those treated with androgen depriva-
tion alone (34.2 vs 15.3 mo; hazard ratio [HR] 0.37; 95% CI
0.17–0.81; p = 0.014). Nuclear AR-V7 expression at HSPC
biopsy was associated with time to castration resistance in
patients treated with systemic therapy exclusively (HR:
Table 1 – Baseline characteristics for 37 patients with castration-
resistant prostate cancer
Parameter Results
Median age, yr (IQR) 67.5 (64.2–75.3)
ECOG PS, n (%)
0 4 (10.8)
1 32 (86.5)
2 1 (2.7)
Visceral metastasis (n)
Present 12
Lung 4
Liver 7
Adrenal 1
Median haemoglobin, g/l (IQR) 113.0 (105.0–124.5)
Median ALP, IU/l (IQR) 142.0 (69.5–448.5)
Median albumin, g/l (IQR) 34.0 (32.0–36.5)
Median LDH, IU/l (IQR) 204.0 (149.3–290.3)
Treatment at/before biopsy, n (%)
Docetaxel 28 (75.7)
Cabazitaxel 9 (24.3)
Abiraterone 20 (54.1)
Enzalutamide 3 (8.1)
IQR = interquartile range; ECOG PS = Eastern Cooperative Oncology Group
performance status; ALP = alkaline phosphatase; LDH = lactate
dehydrogenase.
E U RO P E AN URO LOGY 7 0 ( 2 0 1 6 ) 5 9 9 – 6 0 8 6051.02, 95% CI 1.002–1.032; p = 0.03), but not among those
who received radical treatment (HR 1, 95% CI 0.988–1.008;
p = 0.634; Supplementary Fig. 6A,B).
3.5. Nuclear AR-V7 expression and the nuclear AR-V7/AR-NTD
expression ratio are associated with worse CRPC prognosis
Thirty-seven patients had CRPC biopsies andwere evaluable
for OS from time of CRPC biopsy. As the prognostic
significance of AR-V7 protein levels using EP343 has not
been evaluated in patient tissue, we investigated the
association of nuclear AR-V7 expression, nuclear AR-NTD
expression, and the nuclear AR-V7/AR-NTD ratio in CRPC[(Fig._4)TD$FIG]
A
B
C
AR-V7 HS Media
1st terle ≤ 96.67 15.
2nd terle >96.67 to ≤143.33 10.
3rd terle > 143.33 7.1
AR-NTD HS Media
1st terle ≤ 136.67 6.
2nd terle >136.67 to ≤210 9.8
3rd terle > 210 14
AR-V7/AR-NTD rao Media
1st terle ≤0.5 15.6
2nd terle >0.5 to ≤0.81 9.6
3rd terle > 0.81 8.
Fig. 4 – Nuclear AR-V7 and AR-V7/AR-NTD ratio but not nuclear AR-NTD expre
prostate cancer biopsy. The patient cohort was divided by tertiles for (A) nucle
ratio, and p values for a linear trend test (orthogonal polynomial coefficients)
interval; HR = hazard ratio.biopsies with OS from time of CRPC biopsy. Baseline
characteristics for the 37 patients included in these analyses
are shown in Table 1. Median OS from time of CRPC biopsy
was 10.7 mo (95% CI 8.9–12.5). Nuclear AR-V7 (continuous
variable) was significantly associated with OS (HR 1.012,
95% CI 1.004–1.020; p = 0.003). We divided the patient
cohort into tertiles of nuclear AR-V7 expression; median OS
was 15.6mo (95% CI 9.6–21.6) for patients in the first tertile
(HS 96.7), 10.7 mo (95% CI 8.3–13.1) for patients in the
second tertile (HS >96.7–143.3), and 7.1 mo (95% CI 3.1–
11.2) for patients in the third tertile (HS >143.3; Figs. 4 and
5A). There was a significant linear trend in the univariate
Cox regression model (p = 0.002).
In contrast to nuclear AR-V7 expression, nuclear AR-NTD
expression was not significantly associated with OS from
time of CRPC biopsy (HR 0.998, 95% CI 0.993–1.003;
p = 0.411). Median OS was 6.8 mo (95% CI 0–13.9) for
patients in the first tertile (HS 136.7), 9.8 mo (95% CI 6.9–
12.7) for patients in the second tertile (HS>136.7–210), and
14.8 mo (95% CI 9–20.7) for patients in the third tertile (HS
>210; Fig. 5). The linear trend test was not significant
(p = 0.275; Figs. 4 and 5B). Next we determinedwhether the
nuclear AR-V7/AR-NTD expression ratio was associated
with OS from time of CRPC biopsy. Patients with a lower AR-
V7/AR-NTD ratio had significantly longer OS (HR 2.583, 95%
CI 1.424–4.684; p = 0.002). Median OS was 15.6 mo (95% CI
11.5–19.8) for patients in the first tertile (ratio0.5), 9.6mo
(95% CI 8.4–10.8) for patients in the second tertile (ratio
>0.5–0.81), and 8.8 mo (95% CI 0–17.5) for patients in the
third tertile (ratio >0.81; Figs. 4 and 5C). There was a
significant linear trend in the univariate Cox regression
model (p = 0.017). There were no significant differences in
baseline patient characteristics (age, haemoglobin, albu-
min, alkaline phosphatase, lactate dehydrogenase, visceral
metastasis, and performance status) among tertiles for
nuclear AR-V7, nuclear AR-NTD, or the nuclear AR-V7/AR-
NTD expression ratio (data not shown).n OS (95% CI) HR p value
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Fig. 5 – High nuclear AR-V7 and AR-V7/AR-NTD expression ratio are associated with shorter overall survival (OS) in patients with castration-resistant
prostate cancer (CRPC). Kaplan-Meier curves show OS from time of CRPC biopsy for patients divided by tertiles for (A) nuclear AR-V7, (B) nuclear
AR-NTD, and (C) nuclear AR-V7/AR-NTD expression ratio. Median OS and hazard ratio with 95% confidence intervals are shown, and p values are for a
linear trend test (orthogonal polynomial coefficients).
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Twelve patients had CRPC biopsies before AA treatment and
evaluable PSA response data (Supplementary Table 3). The
median time for CRPC biopsy before AA initiation was
2.0 mo (IQR 0–9). There was a significant association
between themagnitude of PSA decline at 12 wk and the AR-
V7 HS (p = 0.043). Two (17%) patients experienced PSA
responses (50% change from baseline) after 12 wk of
treatment (Supplementary Fig. 7). Patients who responded
to AA had lower median nuclear AR-V7 (n = 2; HS 30, IQR
30–30) than patients who did not respond (n = 10; HS 80,
IQR 45–128.8), although the difference was not significant
(p = 0.197).
4. Discussion
The primary objective of this study was analytical valida-
tion and clinical qualification of a new antibody to the
cryptic exon of AR-V7. This monoclonal antibody detects
AR-V7 but may also bind additional, as yet unidentified,
proteins, although we have shown that the antibody
primarily binds AR-V7 in patient tumour samples. Our
AR-V7 IHC assay is best utilised in conjunction with an AR-
NTD antibody to minimise false positives, as conducted in
our studies. We then evaluated the clinical relevance of IHC
stainingwith this antibody for the following reasons: (1) the
majority of published studies have focused on AR-V7mRNA
expression in circulating tumour cells, with AR-V7 protein
expression having a much longer half-life than AR-V7
mRNA [24]; (2) there are no published data available onmatched HSPC and CRPC tumour samples taken from the
same patient; and (3) this antibody is currently being used
to detect AR-V7 protein in circulating tumour cells as a
putative predictive biomarker in a randomised clinical trial
(NCT02485691).
We observed a significant increase in nuclear AR-V7
protein levels from HSPC to CRPC in our patient cohort, of
which nearly all patients had received docetaxel and AA.
Interestingly, a small subset of patients actually showed the
reverse trend, with a decrease in nuclear AR-V7. We
hypothesise that while some tumours express AR-V7 in
response to androgen ablation, some tumours may acquire
resistance to AA or EZ via increased androgen biosynthesis
that results in lower AR-V7 expression [12]. An alternative
explanation for the decrease may be an increase in other
AR variants that are constitutively active. Although AR-V7
is the most common constitutively active AR variant, we
have recently described a number of AR-Vs detectable in
metastatic biopsy specimens from patients relapsing follow-
ing AA or EZ therapy [25]. Regardless of the mechanism,
however, such biopsies only capture a single time point in
the growth of lethal metastases, so the heterogeneity of
changes in AR-V7 staining is not unexpected.
Importantly, this study highlights that AR-V7 protein
expression is a biomarker of poorer prognosis and increases
with emerging drug resistance. Hornberg et al [26] also
showed that patients with AR-V7 mRNA expression in the
highest quartile had poorer prognosis compared to patients
with lower AR-V7 levels [26]. This association was
confirmed in a study by Antonarakis et al [3] in which
AR-V7 mRNA was determined in metastases as well as in
E U RO P E AN URO LOGY 7 0 ( 2 0 1 6 ) 5 9 9 – 6 0 8 607circulating tumour cells [3]. The present study demon-
strates a significant trend towards poorer outcome among
patients with increased AR-V7 protein expression, in
keeping with previous reports for nonmatched cohorts
[26–28], and points to an association between AR-V7
expression and poor prognosis.
5. Conclusions
This is the first longitudinal report demonstrating increas-
ing AR-V7 protein expression in matched same-patient
biopsies before and after endocrine treatment from patients
with emerging resistance. The data indicate that AR-V7
protein expression increases substantially following cas-
tration in many but not all CRPCs, and that AR-V7 levels are
associatedwith poorer outcome, regardless of AR-FL protein
expression. However, because the rabbit monoclonal
antibody EP343 is not completely specific to AR-V7, its
future use to guide therapeutic choice is best pursued
alongside AR-FL protein expression. These data support the
claimthatAR-V7 is important indriving treatment resistance
in this disease. Moreover, our finding that AR-V7 expression
decreases in some tumours during the emergence of
resistance indicates that AR-V7 expression is not the sole
mechanism underlying treatment resistance in CRPC.
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